Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HCAR1 | Q9BXC0 | 2/20 | 0.37 |
| ▸ | RXRA | P19793 | 2/20 | 0.32 |
| ▸ | GRIN1 | Q05586 | 2/20 | 0.32 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.32 |
| ▸ | RAB9A | P51151 | 1/20 | 0.30 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL1900818 | 0.85 | RAB9A (0.39) | HCAR1RAB9ATDP1 | |
| SCHEMBL5716210 | 0.70 | ALDH1A1 (0.45) | HCAR1RXRAGRIN1GRIN2B | |
| SCHEMBL17361199 | 0.69 | CYP3A4 (0.54) | HCAR1TDP1 | |
| SCHEMBL1893443 | 0.68 | KEAP1 (0.41) | — | |
| SCHEMBL28266410 | 0.68 | RXRA (0.40) | HCAR1RXRAGRIN1GRIN2B | |
| SCHEMBL1895576 | 0.67 | KDM4E (0.41) | — | |
| SCHEMBL2753711 | 0.66 | RXRA (0.38) | HCAR1RXRAGRIN1GRIN2B | |
| SCHEMBL2096061 | 0.66 | RXRA (0.35) | HCAR1RXRAGRIN1GRIN2B | |
| SCHEMBL2751482 | 0.64 | RXRA (0.38) | HCAR1RXRAGRIN1GRIN2B | |
| SCHEMBL5809497 | 0.62 | ALDH1A1 (0.54) | RXRAGRIN1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 35 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8765791-B2 | Method of treating cancer using a neuropeptide Y 5R (NP Y5R) antagonist | UNIVERSITY HEALTH NETWORK (CA) | 2014-07-01 | — | — | US | disclosed |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK | 2011-05-12 | — | — | US | disclosed |
| EP-2262499-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | University Health Network (CA) | 2010-12-22 | — | — | EP | disclosed |
| WO-2009111868-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | UNIVERSITY HEALTH NETWORK (CA) | 2009-09-17 | — | — | WO | disclosed |
| EP-1635813-A4 | COMBINATION THERAPY FOR THE TREATMENT OF DYSLIPIDEMIA | MERCK & CO INC (US) | 2009-07-01 | — | — | EP | disclosed |
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | MERCK SHARP & DOHME CORP. | 2008-03-13 | — | — | US | disclosed |
| EP-1483266-B1 | SPIRO COMPOUNDS WITH NPY ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2008-02-27 | — | — | EP | disclosed |
| EP-1534074-A4 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | MERCK & CO INC (US) | 2008-01-09 | — | — | EP | disclosed |
| US-7304072-B2 | E.g.,cis-N-(4-benzoylphenyl)-4-hydroxy-3'-oxospiro[cyclohexane-1,1'(3'H)-isobenzofuran]-4-carboxamide; useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases, respiratory and urogenital disorders | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2007-12-04 | — | — | US | disclosed |
| EP-1799241-A2 | COMBINATION THERAPY FOR THE TREATMENT OF OBESITY | Merck & Co., Inc. (US) | 2007-06-27 | — | — | EP | disclosed |
| US-20030220499-A1 | Novel spiro compounds | MSD K.K. (JP) | 2003-11-27 | — | — | US | disclosed |
| US-6649624-B2 | Useful as neuropeptide Y receptor antagonists and as agents for therapy of cardiovascular disorders, central nervous system disorders, metabolic diseases | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2003-11-18 | — | — | US | disclosed |
| EP-1204663-B1 | NOVEL SPIRO COMPOUNDS WITH NEUROPEPTIDE Y ANTAGONISTIC ACTIVITY | BANYU PHARMA CO LTD (JP) | 2003-10-29 | — | — | EP | disclosed |
| US-20030055251-A1 | Novel spiro compounds | MSD K.K. (JP) | 2003-03-20 | — | — | US | disclosed |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | MSD K.K. (JP) | 2002-11-07 | — | — | US | disclosed |
| US-6462053-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; CARDIOVASCULAR AND CENTRAL NERVOUS SYSTEM DISORDERS AND METABOLIC DISEASES; HYPERTENSION, NEPHROPATHY, HEART DISEASE, VASOSPASM, ARTERIOSCLEROSIS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-10-08 | — | — | US | disclosed |
| US-6388077-B1 | CARDIOVASCULAR DISORDERS; CENTRAL NERVOUS SYSTEM DISORDERS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-05-14 | — | — | US | disclosed |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | MSD K.K. (JP) | 2002-05-02 | — | — | US | disclosed |
| US-6335345-B1 | NEUROPEPTIDE Y RECEPTOR ANTAGONISTS; OBESITY AND BULIMIA TREATMENT; CENTRAL NERVOUS SYSTEM, PSYCHOLOGICAL, METABOLIC AND EATING DISORDERS; ANTIDIABETIC AGENTS | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2002-01-01 | — | — | US | disclosed |
| US-6326375-B1 | CONTAINING AN UREA GROUP | BANYU PHARMACEUTICAL CO., LTD. (JP) | 2001-12-04 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080064632-A1 | Combination Therapy for the Treatment of Obesity | NPY4R, GPR119, GIPR | HCAR1 294/4885RXRA 549/4885GRIN1 3035/4885 |
| US-20020052371-A1 | NOVEL SPIRO COMPOUNDS | GPR119, NPY1R, OPRK1 | HCAR1 823/4885RXRA 2283/4885GRIN1 46/4885 |
| US-20030055251-A1 | Novel spiro compounds | NPY1R, GPR119, OPRK1 | HCAR1 875/4885RXRA 2161/4885GRIN1 54/4885 |
| US-20030220499-A1 | Novel spiro compounds | NPY1R, OPRK1, OPRM1 | HCAR1 1019/4885RXRA 2271/4885GRIN1 39/4885 |
| US-20110112102-A1 | METHOD OF TREATING CANCER USING A NEUROPEPTIDE Y 5R (NP Y5R) ANTAGONIST | NPY5R, NPY1R, SSTR5 | HCAR1 590/4885RXRA 2430/4885GRIN1 1462/4885 |
| US-20020165391-A1 | Neuropeptide Y receptor antagonists | NPY1R, NPY2R, NPY4R | HCAR1 495/4885RXRA 923/4885GRIN1 66/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.